[1] ALSHAER W, ZUREIGAT H, AL KARAKI A, et al. siRNA:Mechanism of action, challenges, and therapeutic approaches[J]. Eur J Pharmacol, 2021, 905:174-178. [2] 王菲菲, 符合, 任进, 等. siRNA药物研究进展[J]. 中国新药杂志, 2022, 31(5):427-434. [3] ADAMS D, GONZALEZ-DUARTE A, ƠRIORDAN W D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis[J]. N Engl J Med, 2018, 379(1):11-21. [4] HOY S M. Patisiran:first global approval[J]. Drugs, 2018, 78(15):1625-1631. [5] LIU W T, LO Y L, HSU C, et al. CS-PEI/beclin-siRNA downregulate multidrug resistance proteins and increase paclitaxel therapeutic efficacy against NSCLC[J]. Mol Ther Nucleic Acids, 2019, 17:477-490. [6] 侯召丽, 王艳玲, 王雅鹃, 等. siRNA的定量方法及其在药代动力学检测中的应用[J]. 中国生化药物杂志, 2012, 33(4):491-494. [7] NEUGEBAUER M, GRUNDMANN C E, LEHNERT M, et al. Analyzing siRNA concentration, complexation and stability in cationic dendriplexes by stem-loop reverse transcription-qPCR[J]. Pharmaceutics, 2022, 14(7):1348. [8] 张志, 张瑀峣, 顾景凯. 脂质体药代动力学分析方法研究进展[J]. 中国医药工业杂志, 2019, 50(10):1172-1179. [9] 李莎莎, 孙云娟, 董立厚. siRNA药物研究进展及定量分析方法[J]. 中国临床药理学杂志, 2020, 36(18):2926-2930. [10] OUDE BLENKE E, EVERS M J W, BAUMANN V, et al. Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles[J]. Int J Pharm, 2018, 548(2):793-802. [11] GREEN M R, SAMBROOK J. Quantification of RNA by real-time reverse transcription-polymerase chain reaction (RT-PCR)[J]. Cold Spring Harb Protoc, 2018, 2018(10):pdb.prot095042. [12] 问天娇, 高媛, 陈喃喃, 等. 多药耐药1基因小干扰RNA阳离子脂质体逆转乳腺癌多药耐药的研究[J]. 中国药学杂志, 2015, 50(9):763-767. [13] SAW P E, SONG E W. siRNA therapeutics:a clinical reality[J]. Sci China Life Sci, 2020, 63(4):485-500. [14] SUBHAN M A, TORCHILIN V. siRNA based drug design, quality, delivery and clinical translation[J]. Nanomed Nanotechnol Biol Med, 2020, 29:102239. [15] 张曼玉, 楼晨曦, 曹傲能. 主动靶向载药脂质体在肿瘤治疗中的研究进展[J]. 生物医学工程学杂志, 2022, 39(3):633-638. [16] CONSTANTINESCU C A, FUIOR E V, REBLEANU D, et al. Targeted transfection using PEGylated cationic liposomes directed towards P-selectin increases siRNA delivery into activated endothelial cells[J]. Pharmaceutics, 2019, 11(1):47. [17] LEE J J, AHN H J. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy[J]. Biochem Biophys Res Commun, 2018, 503(3):1716-1722. [18] PEI Y, HANCOCK P J, ZHANG H C, et al. Quantitative evaluation of siRNA delivery in vivo[J]. RNA, 2010, 16(12):2553-2563. [19] GREEN M R, SAMBROOK J. Analysis and normalization of real-time polymerase chain reaction (PCR) experimental data[J]. Cold Spring Harb Protoc, 2018, 2018(10):195-197. [20] ALMEIDA B, NAG O K, ROGERS K E, et al. Recent progress in bioconjugation strategies for liposome-mediated drug delivery[J]. Molecules, 2020, 25(23):5672. |